关于全资子公司涉及重大诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、案件所处的诉讼阶段：一审审理中，尚未作出判决。 证券代码：300314 证券简称：戴维医疗 公告编号：2026-007 宁波戴维医疗器械股份有限公司 2、上市公司所处的当事人地位：宁波戴维医疗器械股份有限公司（以 下简称"公司"）的全资子公司宁波维尔凯迪医疗器械有限公司（以下简 称"维尔凯迪"）为两案的被告。 3、涉案的金额：两案合计16,126万元，该涉案金额为原告提起诉讼 及庭审期间变更诉讼请求后的金额，不代表法院最终审理结果。 4、对上市公司损益产生的影响：鉴于案件尚未作出判决，目前无法 准确判断其对本期利润或期后利润的影响。公司高度重视该涉诉事项，并 将根据诉讼进展情况及时履行信息披露义务，敬请投资者注意投资风险。 一、本次重大诉讼事项受理的基本情况 维尔凯迪分别于2025年5月20日及2025年7月7日收到江苏省南京市中 级人民法院送达的相关法律文书（案号：（2025）苏01民初1355号、（2025） 苏01民初1356号、（2025）苏01民初1 ...

Group 1 - The core point of the article is that David Medical (300314) has approximately 18,600 shareholders as of February 13, 2026 [1]

Group 1 - The company responded to an investor inquiry regarding the number of shareholders as of February 20, stating that the total number of shareholders is approximately 18,600 [1]

Group 1 - The core point of the article is that David Medical (300314) has approximately 18,800 shareholders as of February 10, 2026 [1]

Core Insights - The core viewpoint of the article highlights the growing popularity of spectral therapy technology due to its non-drug, non-invasive, and low side-effect characteristics, leading to increased market penetration from professional medical institutions to home and personal consumption scenarios [1] Industry Overview - Spectral therapy devices utilize specific wavelengths (0.4-3.6μm) to irradiate the human body, achieving therapeutic purposes through photothermal effects, photochemical actions, and biological stimulation [2] - Common product names include visible light therapy devices, photon therapy devices, and red/blue light therapy devices [2] Market Size - The market size of China's spectral therapy device industry is projected to reach 244 million yuan in 2024, with a year-on-year growth of 3.83%, driven by the expansion of medical beauty demand, grassroots medical equipment upgrade policies, and consumption upgrades [8][9] Key Companies - Shenzhen Pumen Technology Co., Ltd. has obtained Class II medical device registration for its spectral therapy devices, covering multiple wavelengths [9] - Ningbo David Medical Co., Ltd. specializes in neonatal jaundice treatment devices using patented spectral technology [10] Industry Development Trends 1. **Technological Integration and Innovation**: The industry is transitioning from single-wavelength output to multi-spectral dynamic combinations, integrating AI for personalized treatment plans [11] 2. **Application Scenario Extension**: The use of spectral therapy devices is expanding from cosmetic applications to serious medical treatments, including tumor adjuvant therapy and chronic pain management [12] 3. **Industry Structure Reconstruction**: The industry is experiencing consolidation, with stricter regulations leading to increased market share for leading companies, while smaller brands may exit due to insufficient technological investment [13]

Group 1 - The company, David Medical, announced a change in its production scope to include "Class II: 15-01 - Operating Tables" [1] - The company has obtained a revised Medical Device Production License issued by the Zhejiang Provincial Drug Administration [1]

许可证编号：浙药监械生产许20100125号 证券代码：300314 证券简称：戴维医疗 公告编号：2026-006 宁波戴维医疗器械股份有限公司 关于变更医疗器械生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）因生产经营需要， 对生产范围进行了变更，在原有基础上增加了"第Ⅱ类：15-01-手术台"， 并于近日取得了由浙江省药品监督管理局颁发的变更后的《医疗器械生产许 可证》。变更后的具体信息如下： 生产范围：第Ⅲ类：08-03-急救设备；第Ⅱ类：02-12-手术器械-穿刺 导引器，02-13-手术器械-吻（缝）合器械及材料，07-03-生理参数分析测 量设备，07-04-监护设备，08-03-急救设备，08-05-呼吸、麻醉、急救设备 辅助装置，08-07-医用供气排气相关设备，09-02-温热（冷）治疗设备/器 具，09-03-光治疗设备，14-06-与非血管内导管配套用体外器械，14-15- 病人护理防护用品，15-01-手术台，15-05-患者转运器械*** 许可期限：自2025年1月1 ...

Group 1 - The core point of the article is that David Medical (300314) has approximately 18,600 shareholders as of January 30, 2026 [1]

Group 1 - The core point of the article is that David Medical responded to an investor inquiry regarding the number of shareholders as of January 31, 2026, stating that the total number of shareholders is approximately 18,600 [1] Group 2 - The company expressed gratitude for the investor's interest in their shareholder information [1]

Core Viewpoint - David Medical announced an expected net profit attributable to shareholders of 75 million to 95 million yuan for the fiscal year 2025, representing a growth of 30.97% to 65.90% compared to the previous year's profit of 57.26 million yuan [1] Financial Performance - The projected net profit for 2025 is estimated to be between 75 million and 95 million yuan [1] - This represents an increase of 30.97% to 65.90% from the previous year's net profit of 57.26 million yuan [1]